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busulfan(130-145 mg/m2) and fludarabine (40 mg/m2) x 4 days (t-
IV Bu/Flu) followed by HCT. All were treated with rituximab at
375 mg/m2 on days 1 and 8 after a matched related (n5 7), mis-
matched related (n5 1), matched unrelated(n5 6), or mismatched
unrelated (n5 2) HCT. Two patients received ATG as GVHD
prophylaxis. Median time to neutrophil and platelet engraftment
was 15 and 13 days, respectively. Maximum grades of aGVHD ob-
served were 0 (n5 4), 1(n5 7), 2 (n5 7), and 3 (n5 1). Moderate/
severe cGVHD occurred in only 3/16. With a median F/U of 15
months (range: 2-33), complete response was achieved in 12, per-
sistent residual disease in 3, and progressive disease in 1. CMV re-
activation(n5 8), as well as bacterial (n5 8), fungal (n5 3), and
viral (n5 3) infection did not appear to exceed historical rates with-
out rituximab. After HCT, prolonged lymphopenia was demon-
strated: Median absolute lymphocyte counts (0.84 K/uL)
remained below the reference range through one year. In 5/16 sub-
jects for which B-cell data was available, B-cell lymphopenia per-
sisted to one year after HCT. The addition of rituximab 375 mg/
m2 to t-IV Bu/Flu followed by allogeneic HCT has encouraging
activity in the treatment of lymphoid malignancies. While both ab-
solute and B-cell lymphopenia were observed through one year
after HCT, infectious complications have not exceeded historical
rates.357
THE INCIDENCE OF HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME
(SOS) FOLLOWING A PREPARATIVE REGIMEN OF DOSE TARGETED IN-
TRAVENOUS BUSULFAN AND CYTOXAN AND A GRAFT VERSUS HOST DIS-
EASE PROPHYLACTIC REGIMEN OF TACROLIMUS AND METHOTREXATE:
A SINGLE INSTITUTION EXPERIENCE
Aljitawi, O.S.1, DuBois, L.2, O’Neal, N.2, Divine, C.1, Ganguly, S.1,
Abhaynkar, S.1, McGuirk, J.L.1 1University of Kansas Medical Center,
Kansas City, KS; 2University of Kansas Medical Center, Kansas City, KS
Hepatic sinusoidal obstruction syndrome (SOS) is a common
complication of preparative regimens in the setting of stem cell
transplantation. The use of intravenous Busulfan (Bu), however, re-
sulted in decrease in the incidence of SOS to 8%. The graft-versus-
host-disease (GVHD) prophylactic regimen seems also to impact
the risk of SOS following an ablative transplant. The goal of this
study is to determine the incidence of clinically significant SOS
in a homogenous cohort of patients who received an ablative regi-
men of dose targeted intravenous Busulfan and cytoxan (Bu/Cy),
and received tacrolimus and methotrexate (Tac/MTX) for
GVHD prophylaxis.
Methods: In this retrospective study, patients who received an
ablative regimen of intravenous Bu/Cy, and received Tac/MTX
for GVHD prophylaxis were identified. Data collected include:
age, indication for transplant, disease status at transplant, stem
cell source, date of transplant, date of onset of clinically signifi-
cant SOS, and date and cause of death. Patients who underwent
an ablative regimen of total body irradiation (TBI) and cytoxan
and received the same GVHD prophylactic regimen were used
for comparison.
Results:Between September, 2007 and August, 2009, 34 patients re-
ceived an ablative regimen of intravenous Bu/Cy and GVHD pro-
phylactic regimen of Tac/MTX. In this cohort, age ranged from
25 to 63 years old. Diagnoses were as follows: AML n5 20, MDS
n5 7, CML n5 4, myelofibrosis n5 2, and NHL n5 1. Disease
status at diagnosis was CR1 n5 16, $ CR2 n5 5, relapsed/refrac-
tory n5 2, untreated n5 6, PR n5 3, chronic phase CML n5 2.
In this cohort, only three (8.8%) patients developed clinically signif-
icant SOS. Two patients were diagnosed within 3 weeks of trans-
plant, however, one patient developed biopsy proven SOS 58 days
post transplant. None of the patients in this cohort died of SOS.
In 28 out of 34 patients, Bu pharmacokinetic (PK) studies were
done properly. In two patients the Bu dose was increased and in
one case the dose was decreased. In the comparison cohort, 29 pa-
tients received TBI/Cy conditioning regimen. In this cohort only
one patient (3.4%) developed SOS.
Conclusion:The incidence of SOS in the cohort of patients who re-
ceived dose targeted intravenous Bu/Cy and Tac/MTX for GVHDprophylaxis was comparable to the reported incidence of SOS in lit-
erature and appears to be higher than the incidence of SOS in the
TBI/Cy and Tac/MTX cohort.358
COMORBIDITY SCORE IN ALLOGENEIC MYELOABLATIVE TRANSPLANTS
CONDITIONED WITH FLUDARABINE/I.V. BUSULFAN (FLUBU4)
Patel, P., Sweiss, K., Peace, D., Quigley, J., Chen, Y.-H., Mahmud, N.,
Rondelli, D. University of Illinois at Chicago
The assessment of comorbidity score was previously demon-
strated to predict the risk of transplant related mortality (TRM) in
patients undergoing standard myeloablative allogeneic hematopoi-
etic stem cell transplantation (HSCT). Since Flu/Bu4 regimen has
been associated with limited extra-hematologic toxicity, we analyzed
whether the comorbidity score may still represent a useful tool in
transplant patients conditioned with this regimen. Of 52 consecutive
patients who received a matched HSCT with FluBu4 at our institu-
tion, 50 were evaluable for assessing their pre-transplant comorbid-
ity score according to the initial description (Sorror M et al. Blood
2005, 106:2912). The total dose of I.V. Bu was 12.8 mg/kg in 18 pa-
tients while in the remaining patients a targeted dose was given
(AUC: 4800 mM*min). Patients were divided in three groups: group
A, score 0 (n5 8); group B, score 1-2 (n5 16), group C, score$ 3
(n5 26). The three groups did not differ significantly in age, diagno-
sis, previous lines of chemotherapy, type of donor and targeted vs
standard dose of I.V. Bu. Patients with active acute leukemia at the
time of HSCT were 12% in group A, 18% in group B and 29% in
group C (p5 ns). Thirteen patients (26%) died due to relapse of
their malignancy and 11 (22%) due to transplant-related complica-
tions. TRMwas 12% in group A, 37% in group B and 15% in group
C despite the fact that the rate of acute GVHD grade II-IV was
slightly higher in group C (34%), compared to groups A (12%)
and B (31%). Patients in group C had a trend for higher relapse-re-
latedmortality, 38%, compared to 12%observed in each of the other
groups (p5 0.07). After a median follow-up of 640 days (range: 111-
2065), a greater number of patients were alive and in remission in
group A (75%) (p5 0.04), compared to group B (50%) and C
(34%). In conclusion, a higher comorbidity score correlated with
worse overall survival largely due to increased relapse. However, it
did not predict TRM in patients conditioned with FluBu4.359
CHILDREN WITH ACUTE LEUKEMIA: A COMPARISON OF OUTCOMES
FROM ALLOGENEIC BLOOD STEM CELL AND BONE MARROW TRANS-
PLANTATION
Lin, Y.-F.1, Lairson, D.R.2, Chan, W.2, Du, X.L.2, Leung, K.S.1, Ken-
nedy-Nasser, A.A.1, Martinez, C.A.1, Bollard, C.M.1,
Gottschalk, S.M.1, Heslop, H.E.1, Brenner, M.K.1, Krance, R.A.1 1Baylor
College of Medicine, Houston, TX; 2School of Public Health, University of
Texas Health Science Center at Houston, Houston, TX
The relative merits of PBSCT versus BMT for children with stan-
dard and high risk hematologicmalignancies remain unclear. In a ret-
rospective single center study, we compared allogeneic peripheral
blood stem cell transplantation (PBSCT) (n5 30) with bonemarrow
transplantation (BMT) (n5 110) in children with acute leukemia be-
tween January 1st, 2001 and September 30th, 2006. Four (13.3%)
PBSCT patients received HLA identical sibling donors versus 38
(34.5%) who received marrow: 15 (50.0%) PBSCT recipients re-
ceived HLA mismatched PBSC versus 10 (9.1%) receiving marrow.
Nine (30.0%) PBSCT patients had an HLA matched unrelated do-
nor versus 49 (44.5%) of marrow recipients. Two PBSCT (6.7%)
were from mismatched unrelated donors versus 13 (11.8%) in the
marrow recipients. The median age for PBSCT was 9 years versus
8 years for BMT. Descriptive statistics were used to summarize the
demographic and medical variables. The unadjusted probabilities
of disease-free survival were estimated using the Kaplan-Meier
method. The association of graft-source and time to each of the
study endpoints was estimated by Cox’s regressionmodel and the oc-
currence of GvHD was included as a time-dependent covariate.
Time to both neutrophil engraftment and platelet independence
Poster Session II S291was faster after PBSCT than BMT (neutrophils 14.5 d versus 18.0 d,
p\0.001; platelets, 23.1 d versus 28.7 d, p5 0.034). The cumulative
incidence of grade II – IV acute graft-versus-host-disease at 100 days
was 10.4% after PBSCT and 15.1% after BMT (p5NS). The cu-
mulative incidence of chronic graft-versus-host disease was 13.8%
after PBSCT and 11.3% after BMT (p5NS). Standard disease
risk was defined as ALL or AML in first or second remission or
with unfavorable prognoses. The high risk category was confined
in third or subsequent remission or in relapse. One year disease-
free survival in standard risk disease was 61.5% after PBSCT and
81.3% after BMT (p5NS). In high risk disease, 1 year survival
was 18.8% after PBSCT and 25.8% after BMT (p5NS). In multi-
variate analysis, only disease risk and pre-transplant CMV seroposi-
tivity were significant predictors of disease-free survival. HLA
typing, CD 34 depletion, and occurrence of acute or chronic
GvHD were included as independent variables but were not signifi-
cant prognostic factors associated with treatment-related mortality,
relapse or disease-free survival. We conclude that PBSCT for chil-
dren produces faster engraftment without increased risk of acute
or chronic GvHD.360
REDUCED-INTENSITY ALLOGENEIC BONE MARROW TRANSPLANTATION
WITHOUT INCLUSION OF TOTAL BODY IRRADIATION FOR A CHILDWITH
DYSKERATOSIS CONGENITA
Powell, J.L., Frantz, C.N., Kolb, E.A. Alfred I. duPont Hospital for Chil-
dren, Wilmington, DE
A 20 month old, ex 33 week gestation male with a history of cere-
bral palsy, retinopathy of prematurity, moderate developmental de-
lay, and periventricular leukoencephalopathy presented during
a febrile episode with a platelet count of 102 k/ml. A CBC obtained
8 months previously had a platelet count of 508 k/ml with otherwise
normal white count and hemoglobin.Over the course of his hospital-
ization, his platelet count fell to 41 k/microliter.His hemoglobinwas
10.6 g/dL with an MCV of 93 fL; his white blood cell count was
3.6 k/microliter. His thrombocytopenia continued to worsen, and
he developed neutropenia\750 k/microliter. Physical examination
included dystrophic finger/toe nails. Evaluation for for dyskeratosis
congenita via telomere length measurement was obtained. He was
found to have amedian telomere length of 7.9 kb for his lymphocytes
and 8.9 kb for his granulocytes, both of which are very low in com-
parison to laboratory established normals. DKC1, TERC, and
TERT gene evaluations revealed no mutation. Pancytopenia wors-
ened rapidly (hemoglobin \7 g/dL, ANC\0.5 k/microliter,
platelets\10 k/microliter), and we decided to pursue stem cell
transplantation. He received a reduced intensity transplant using flu-
darabine (25 mg/m2/q 24 hours  5 doses on days -7 to -3), cyclo-
phosphamide (400 mg/m2 q 24 hours  4 doses on days -6 to -3),
rabbit ATG (3.75 mg/kg q 24 hours  4 doses on days -5 to -2).
GVHprophylaxis was provided with cyclosporine andmethotrexate.
He received a 10/10 matched unrelated bone marrow transplant.
Donor and recipient were both CMV negative. Transplant was
well tolerated by the patient except for allergic reactions to ATG.
The patient experienced grade II skin GVH, treated with cyclospor-
ine and prednisolone. Neutrophil engraftment occurred on day +12;
platelet engraftment occurred on day +25, and red cell engraftment
by day +37. The patient was discharged to home on day +25. Engraft-
ment studies have remained 100% donor from day +12 to the most
recent examination on day +370. The patient has had resolution of
his cytopenias. This patient represents the first US report of
a non-radiation containing, reduced intensity transplant regimen
for a patient with dyskeratosis congenita.361
THE DURATION OF THE EX VIVO TRANSPORTATION OF HEMATOPOIETIC
STEM CELLS DOES NOT SEEM TO IMPAIR THE CLINICAL OUTCOME FOL-
LOWING TRANSPLANTATION – A SINGLE CENTRE STUDY
Olsson, R., Remberger, M., Ringden, O. Karolinska University Hospital,
Stockholm, Sweden
In hematopoietic stem cell transplantation (HSCT), using un-
related donors, stem cells are often harvest at remote hospitals,and may be handled ex vivo for several days before they are in-
fused into the recipient. Thus, the aim of this study was to inves-
tigate whether the duration of the ex vivo transportation of
hematopoietic stem cells impairs the clinical outcome following
transplantation. We retrospectively analyzed 90 consecutive pa-
tients who received unrelated donor hematopoietic stem cells at
our centre between 2003 and 2008. Both children and adults
were included (median age 45, range 0.5-67), whereas retrans-
plantations were excluded. The indications for allogeneic
HSCT were: AML (32%), ALL (16%), myelodysplastic syn-
drome (16%), CML (10%), lymphoma (12%), solid tumors
(7%), metabolic disorders (3%), aplastic anemia (2%), and multi-
ple myeloma (2%). In all recipients, the total ex vivo time of the
stem cell transplant (median 28 h, range 5-53 h) was calculated
and subdivided into the transportation time from the donor hos-
pital to our centre (median 20 h, range 3-38 h), as well as the
time from arrival at our hospital until the start of the stem cell
infusion (median 10 h, 0.5-26 h). In univariate analysis, none of
the ex vivo times were significant predictors of graft failure, re-
lapse, non-relapse mortality or overall survival. In conclusion,
the clinical outcome following HSCT seems to be independent
of the time the stem cell transplant is kept ex vivo for transpor-
tation purposes.362
HIGH RABBIT-ANTI-HUMAN THYMOCYTE GLOBULIN SERUM LEVELS
ARE ASSOCIATED WITH LOW LIKELIHOOD OF GRAFT-VS-HOST DISEASE
AND HIGH LIKELIHOOD OF POSTTRANSPLANT LYMPHOPROLIFERATIVE
DISORDER
Ugarte-Torres, A.1, Podgorny, P.J.1, Liu, Y.1, Russell, J.A.2, Storek, J.2
1University of Calgary, Calgary, AB, Canada; 2Alberta Health Services,
Calgary, AB, Canada
Background:Rabbit-anti-human T cell globulin (ATG) has the po-
tential to decrease the likelihood of graft-vs-host disease (GVHD) or
graft failure and to increase the likelihood of relapse or infections.
After a given ATG dose, serum ATG levels are variable, presumably
due to variable clearance.
Patients andMethods:We determined ATG levels on day 7 and 28
in 160 recipients of allogeneic marrow or blood stem cells, whose
conditioning included 4.5 mg/kg ATG (Thymoglobulin, Genzyme).
Median follow up was 419 days (range, 14-1519).
Results: Patients with grade 2-4 acute GVHD as well as patients
with extensive chronic GVHD had lower and patients with post-
transplant lymphoproliferative disorder (PTLD) had higher median
ATG levels on day 7 as well as day 28. In multivariate analysis, pa-
tients with day 7 ATG levels above 1.109 mg/ml had 0.38-fold risk
of developing grade 2-4 acute GVHD compared to patients with
lower ATG levels (p5 0.02), patients with day 7 levels above
0.673 mg/ml had 0.44-fold risk of developing extensive chronic
GVHD (p5 0.009), and patients with day 7 ATG levels above
1.436 mg/ml had 8.30-fold risk of developing PTLD (p5 .001).
There was no association of either day 7 or day 28 ATG levels
with relapse, non-PTLD infections or death. Association with graft
failure could not be evaluated due to only 4 graft failures in the
cohort.
Conclusion: Patients with slow clearance of ATG have a low risk of
acute and chronic GVHD but a high risk of PTLD.363
EARLY COMPLETE DONOR LYMPHOID CHIMERISMWITH FLUDARABINE,
MELPHALAN AND LOW DOSE (400 CGY) TOTAL BODY IRRADIATION RE-
DUCED INTENSITY CONDITIONING
Hepgur, M.1, Saito, N.2, Hahn, T.2, Starostik, P.3, Wallace, P.4,
Bambach, B.2, Higman, M.2, Dubel, K.2, McCarthy, P.2,
Battiwalla, M.2 1University at Buffalo, Buffalo, NY; 2Roswell Park Can-
cer Institute, Buffalo, NY; 3Roswell Park Cancer Institute, Buffalo, NY;
4Roswell Park Cancer Institute, Buffalo, NY
Background: Delayed acquisition of complete donor lymphoid
chimerism may contribute to relapse in 200 cGy total body
